William Blair Brokers Increase Earnings Estimates for APLS

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Research analysts at William Blair raised their Q3 2025 earnings per share estimates for Apellis Pharmaceuticals in a research report issued to clients and investors on Tuesday, April 1st. William Blair analyst L. Hanbury-Brown now expects that the company will earn ($0.15) per share for the quarter, up from their prior forecast of ($0.17). The consensus estimate for Apellis Pharmaceuticals' current full-year earnings is ($1.70) per share. William Blair also issued estimates for Apellis Pharmaceuticals' Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.73) EPS and Q1 2026 earnings at $0.02 EPS.

Several other analysts have also issued reports on APLS. Scotiabank upped their target price on shares of Apellis Pharmaceuticals from $30.00 to $31.00 and gave the stock a "sector perform" rating in a research note on Wednesday, April 2nd. JPMorgan Chase & Co. upped their target price on Apellis Pharmaceuticals from $50.00 to $54.00 and gave the company an "overweight" rating in a report on Tuesday, March 4th. Royal Bank of Canada cut their price objective on Apellis Pharmaceuticals from $26.00 to $25.00 and set a "sector perform" rating on the stock in a research report on Monday, March 3rd. Wedbush lowered their target price on Apellis Pharmaceuticals from $30.00 to $29.00 and set a "neutral" rating on the stock in a research note on Monday, March 3rd. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $57.00 price objective on shares of Apellis Pharmaceuticals in a research report on Monday, March 3rd. Eight analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Apellis Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $45.59.

Apellis Pharmaceuticals Stock Up 3.6 %

APLS stock traded up $0.68 during mid-day trading on Friday, reaching $19.38. 880,037 shares of the company traded hands, compared to its average volume of 2,110,316. The stock has a market cap of $2.43 billion, a price-to-earnings ratio of -9.67 and a beta of 0.85. The firm's 50 day moving average price is $25.59 and its 200 day moving average price is $28.67. Apellis Pharmaceuticals has a fifty-two week low of $17.72 and a fifty-two week high of $57.85. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last released its quarterly earnings data on Friday, February 28th. The company reported ($0.29) earnings per share for the quarter, beating analysts' consensus estimates of ($0.37) by $0.08. The firm had revenue of $212.50 million for the quarter, compared to analyst estimates of $197.92 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The business's quarterly revenue was up 45.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.73) earnings per share.

Insider Transactions at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, CFO Timothy Eugene Sullivan sold 2,170 shares of the company's stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $28.70, for a total value of $62,279.00. Following the transaction, the chief financial officer now directly owns 88,100 shares in the company, valued at $2,528,470. This represents a 2.40 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Cedric Francois sold 6,247 shares of the firm's stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $28.70, for a total value of $179,288.90. Following the completion of the sale, the chief executive officer now directly owns 307,415 shares in the company, valued at approximately $8,822,810.50. The trade was a 1.99 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 63,238 shares of company stock valued at $1,857,510. 6.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Several hedge funds have recently bought and sold shares of the stock. EverSource Wealth Advisors LLC raised its position in shares of Apellis Pharmaceuticals by 2,707.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company's stock valued at $25,000 after buying an additional 758 shares in the last quarter. Signaturefd LLC lifted its stake in Apellis Pharmaceuticals by 357.2% during the fourth quarter. Signaturefd LLC now owns 1,175 shares of the company's stock worth $37,000 after purchasing an additional 918 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of Apellis Pharmaceuticals in the 4th quarter worth about $83,000. US Bancorp DE increased its position in shares of Apellis Pharmaceuticals by 70.0% during the 4th quarter. US Bancorp DE now owns 3,223 shares of the company's stock valued at $103,000 after purchasing an additional 1,327 shares during the last quarter. Finally, Covestor Ltd raised its holdings in shares of Apellis Pharmaceuticals by 1,819.2% during the 4th quarter. Covestor Ltd now owns 3,992 shares of the company's stock valued at $127,000 after buying an additional 3,784 shares in the last quarter. 96.29% of the stock is currently owned by institutional investors.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).